+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 16Years +
All Genders
ID05587894

Optimizing Combination and Duration of Antiviral Therapy in Immunocompromised Patients with COVID-19 The OPTICOV Randomized Controlled Trial

Led by ANRS, Emerging Infectious Diseases · Updated on 2026-10-19

256

Participants Needed

18

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of antiviral treatments in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19. This trial compares a combination therapy of remdesivir and nirmatrelvirritonavir DAA against nirmatrelvirritonavir alone, and also evaluates whether extending nirmatrelvirritonavir treatment from 5 to 10 days improves viral outcomes. The study is a randomized, controlled, factorial, superiority trial involving 256 participants from France and Switzerland. Participants will be randomly assigned to one of four study groups nirmatrelvirritonavir for 5 days, nirmatrelvirritonavir for 10 days, nirmatrelvirritonavir for 5 days plus a single dose of remdesivir, or nirmatrelvirritonavir for 10 days plus a single dose of remdesivir. Nirmatrelvirritonavir is an oral protease inhibitor combination taken twice daily, while remdesivir is given as a 200 mg intravenous infusion. Those not eligible or unwilling to participate in randomization may join a non-comparative exploratory cohort. During the study, participants will undergo assessments including nasopharyngeal swabs for viral load measurement by RT-PCR at multiple timepoints, blood tests, and symptom evaluations using FLU-PRO-Plus scores. Researchers will monitor viral load changes, emergence of mutations, hospitalization, death, post-COVID-19 conditions, adverse events, drug interactions, and treatment adherence. The primary outcome is the percentage of patients with a viral load threshold below a cycle threshold of 32 at Day 10 after treatment starts. The total study duration extends up to Day 90 for follow-up measurements.

CONDITIONS

Brief Title

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Research Team

D

Douae Ammour

C

Chiara Fedeli

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here